Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Electrodermal Hyporeactivity And Depression (EUDOR-A)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02915757
Recruitment Status : Unknown
Verified July 2016 by University Hospital, Montpellier.
Recruitment status was:  Active, not recruiting
First Posted : September 27, 2016
Last Update Posted : September 27, 2016
Sponsor:
Collaborators:
University of Molise
EMOTRA-AB, Göteborgsvagen 74, 433 63 Sävedalen, Sweden
Information provided by (Responsible Party):
University Hospital, Montpellier

Brief Summary:
Suicide, suicide attempts and depression are major social problems. The present research program focuses on the relationship between electrodermal hyporeactivity, as measured by the ElectroDermal Orienting Reactivity (EDOR) Test, and suicide and suicide attempts with death intent in patients with a primary diagnosis of depression. Electrodermal hyporeactivity has in several publications from different laboratories repeatedly been shown to have a high sensitivity (up to 97%) and high raw specificity (up to 98%) for suicide. Such levels are unique in psychiatry. The relationship between suicidal propensity and hyporeactivity can be considered as strongly significant. Almost all evidence in the topic up today has been established in research settings with specific exclusion criteria for some secondary psychiatric and some somatic illnesses. However, it is important to study the relationship between electrodermal hyporeactivity and suicide in relatively unselected patients regarding secondary psychiatric diagnoses and somatic diagnoses in a natural clinical ward situation and milieu. A previous naturalistic study proved that a test of electrodermal hyporeactivity fits very well into the daily clinical work.

Condition or disease Intervention/treatment Phase
Depression Diagnosis Device: EDOR test Not Applicable

Detailed Description:

This EUDOR-A study is a naturalistic, european and multicentric study. In France, patient's recruitment will be only conducted by investigators within the Department of Psychiatric Emergencies and Post Acute Care, University Hospital of Montpellier.

Over one year, 233 patients suffering from a major depressive episode with (n=70) and without any history of suicide attempt (n=163) will be recruited.

The maximum period of participation for a given patient will be 12 months with 2 phone assessments at 6 month and 12 month.

Inclusion visit: clinical and biological assessment and Edor test. Second and third visits at 6 and 12 month: Follow up visits in the department or interview by telephone in order to assess suicidal ideations or suicide attempts since the inclusion.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 112 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Naturalistic Clinical Studies in Several Centres of Electrodermal Hyporeactivity in Adult Patients With Primary Depression
Study Start Date : March 2015
Estimated Primary Completion Date : March 2017
Estimated Study Completion Date : March 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Depressive patients
EDOR test on depressed patients with or without personal history of suicidal behavior
Device: EDOR test

The ElectroDermal Orienting Reactivity (EDOR) specifically is optimized for the detection of electrodermal hyporeactivity.

The EDOR investigation last about 30 min. The EDOR Test Data is sent immediately after each EDOR Test for each Test Person to a Company named EMOTRA for blind analyses. The EDOR Test Report may change the basis for the assessment and a new risk assessment may be needed to be done.

Blood sample and clinical assessment





Primary Outcome Measures :
  1. Specificity and sensibility of the electrodermal hyporeactivity [ Time Frame: At 6 and 12 month ]
    Correlation between the Edor Test results and suicidal behavior


Secondary Outcome Measures :
  1. The sensibility of the electrodermal hyporeactivity compared with the occurrence of the violent suicidal attempt measured by Columbia-Suicide Severity Rating Scale (C-SSRS) [ Time Frame: At 6 month ]
    Comparison of test result between patients with history of violent suicidal attempt and patients with history of non violent suicidal

  2. The sensibility of the electrodermal hyporeactivity compared with the occurrence of the violent suicidal attempt measured by Columbia-Suicide Severity Rating Scale (C-SSRS) [ Time Frame: At 6 and 12 month ]
    Comparison of test result between patients with history of violent suicidal attempt and patients with history of non violent suicidal

  3. Electrodermal activity in depressive and suicidal patients with or without insomnia. [ Time Frame: At 6 and 12 month ]
    Comparison of test result between patients with insomnia and patient without insomnia. Insomnia will be evaluated with the "Insomnia severity index" (ISI).

  4. Genetic vulnerability to suicidal behavior by polymorphism analysis in blood sample [ Time Frame: At the inclusion ]
    To study the polymorphisms by blood sample analysis of the promotor of Spermidine/Spermine Acetyltransferase 1 (SAT1), Phenylethanolamine N-Methyltransferase (PNMT) and Noradrenalin Transporter (NAT). between depressed patients with suicidal behavior and depressed patients without suicidal behavior.

  5. The sensibility of the electrodermal hyporeactivity compared with the occurrence of the violent suicidal attempt measured by Risk Rescue Rating Scale (RRRS) [ Time Frame: At 6 and 12 month ]
    Comparison of test result between patients with history of violent suicidal attempt and patients with history of non violent suicidal

  6. The sensibility of the electrodermal hyporeactivity compared with the occurrence of the violent suicidal attempt measured by Beck Scale for Suicidal Intent (SIS). [ Time Frame: At 6 and 12 month ]
    Comparison of test result between patients with history of violent suicidal attempt and patients with history of non violent suicidal



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

All subjects men and women will necessarily meet the following inclusion criteria:

  • In- and outpatients, with a diagnosis of primary depression according to the International classification of Disease (ICD-10) should be included as a routine. That is, patients in a primary unipolar major episode or dysthymia or primary depression with a personality disorder or an anxiety disorder as secondary diagnoses and primary bipolar disorder in a non-hypomanic and non-manic phase are expected to be included.
  • Age : 18 years or older
  • written informed consent
  • must belong to social safety system
  • To be able to understand instructions for the EDOR Test, the aim and the methodology of the study.

Exclusion criteria:

  • diagnosed or suspected dementia
  • Acute known or suspected alcohol or other substance abuse. The condition of past substance abuse (i.e. alcohol abuse or dependance, drug abuse or dependance ) should be noted in the comment field of the EDOR Test routine and patient must have been abstinent for at least one year.
  • Serious problems of hearing, the patient should not participate.
  • Refusal of participation
  • Subject deprived of liberty (by judicial or administrative decision)
  • Subject protected by law.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02915757


Locations
Layout table for location information
France
Montpellier University Hospital
Montpellier, France, 34295
Sponsors and Collaborators
University Hospital, Montpellier
University of Molise
EMOTRA-AB, Göteborgsvagen 74, 433 63 Sävedalen, Sweden

Layout table for additonal information
Responsible Party: University Hospital, Montpellier
ClinicalTrials.gov Identifier: NCT02915757     History of Changes
Other Study ID Numbers: UF 9464
2014-A01310-47 ( Other Identifier: Agence Nationale de sécurité des Médicaments )
First Posted: September 27, 2016    Key Record Dates
Last Update Posted: September 27, 2016
Last Verified: July 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by University Hospital, Montpellier:
Depression
EDOR test
Electrodermal hyporeactivity
Additional relevant MeSH terms:
Layout table for MeSH terms
Depression
Depressive Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders